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Introduction {#sec1}
============

Trimethoprim (TMP) is commonly used in the treatment of urinary tract infections (UTIs) caused by *Escherichia coli* and *Klebsiella pneumoniae* ([@bib6]). It is used either alone or in combination with sulfamethoxazole (SMX), which has a slightly different target spectrum. Although TMP and SMX are administered as a combination in the treatment of UTIs, synergy between the two has not been observed *in vivo* and, therefore, prophylaxis or treatment can be carried out using TMP alone ([@bib1], [@bib9]). Owing to relatively low cost, it is the preferred treatment option in developing countries where incidence of UTIs is generally higher. However, in the past several decades, the use of TMP has been limited by the emergence of resistant bacteria in developed and developing countries alike ([@bib23], [@bib26]).

TMP causes the depletion of deoxythymidine monophosphate (dTMP), methionine, glycine, and purines through the competitive inhibition of dihydrofolate reductase (FolA) in the folate pathway ([@bib11]). Not surprisingly, binding site mutations in FolA, which impinge on TMP binding, FolA overexpression, and acquisition of naturally resistant plasmid-borne *dfr* enzymes, are direct mechanisms of resistance in several bacteria ([@bib5], [@bib29], [@bib32]). The currently explored strategies for tackling resistance include synergistic combinations and cycling of antibiotics with collateral sensitivity outcomes; although TMP in combination with SMX and vancomycin has been found to synergistically inhibit wild-type (WT) TMP-sensitive *E. coli in vitro*, some TMP-resistant *E. coli* strains have been observed to be inhibited by TMP-zidovudine ([@bib30], [@bib34]). However, through drug cycling experiments it has been found that TMP-resistant *E. coli* show co-resistance to most other commonly used antibiotics, which indicates involvement of several broad-spectrum resistance mechanisms ([@bib7]). Therefore, identification of a strategic target or inhibitor through systematic investigation of the phenotype merits importance.

Transcriptomic characterization of *E. coli* upon exposure to TMP has shown that, under bacteriostatic and bactericidal conditions, expression of genes involved in the SOS response, pyrimidine synthesis and salvage, DNA repair, and *mar* operon is altered ([@bib24]). Furthermore, activation of acid stress response in *E. coli* has also been observed following exposure to sub-inhibitory concentration of TMP ([@bib14]). Several of these processes can be expected to not only be active in TMP-resistant *E. coli* but also lead to the emergence of vulnerabilities, thereby presenting new opportunities for inhibiting resistant *E. coli*. With an objective of identifying such targetable resistance-associated alterations, we studied laboratory-evolved TMP-resistant *E. coli* using a transcriptome-integrated network approach. Several genes involved in stress response and metabolism were found to be differentially expressed with extensive cross talk between them. Based on the nature of metabolic perturbations, we identified the dependence on serine hydroxymethyltransferase (GlyA), an enzyme in the folate pathway as an emergent vulnerability in TMP-resistant *E. coli*. We demonstrated that the deletion of *glyA* significantly rescues sensitivity to TMP in two laboratory-evolved TMP-resistant *E. coli* strains and a multidrug-resistant (MDR) clinical isolate of uropathogenic *E. coli*. Finally, through a comparative evolution experiment, we observed that acquisition of TMP resistance is slower in the absence of *glyA*.

Results and Discussion {#sec2}
======================

Evolution and Transcriptome of TMP-Resistant *E. coli* {#sec2.1}
------------------------------------------------------

TMP-resistant *E. coli* were evolved from *E. coli* K12 MG1655 (WT) as per previous protocols ([@bib17], [@bib28]). Briefly, in each step of the experiment, the concentration of TMP was doubled and *E. coli* was sub-cultured (initial A~600~ \~ 0.1) when sufficient growth (A~600~ \~ 0.6) at a particular concentration was observed. The minimum inhibitory concentration (MIC) for WT was found to be 0.5 μg/mL (consistent with the MIC expected *in vivo* with a peak serum concentration of TMP, i.e., 1--2.5 μg/mL) ([@bib25]). Two strains---32xR1 and 32xR2---were evolved from biological replicates of WT, i.e., WT1 and WT2, respectively, starting from a sub-inhibitory concentration of 0.125--16 μg/mL ([Figure 1](#fig1){ref-type="fig"}A). Only a minor growth defect was observed for both 32xR strains in the absence and presence of 16 μg/mL TMP indicating that the resistance-associated fitness cost was minimal ([Figure S1](#mmc1){ref-type="supplementary-material"}). The MIC for 32xR1 and 32xR2 was 1,024 and 128 μg/mL, respectively. Both the 32xR strains had the previously characterized Leu28Arg (L28R) TMP-resistant mutation in the binding site of FolA and the −34C\>T mutation in the −35 region of the *folA* promoter, which causes an overexpression of the mutant DHFR ([@bib15], [@bib28]). On an average, *folA* was found to be \~20-fold upregulated in the 32xR *E. coli* ([Table S1](#mmc1){ref-type="supplementary-material"}). The TMP resistance of 32xR *E. coli* can be largely attributed to the presence of these mutations.Figure 1Laboratory-Evolved TMP-Resistant *E. coli* Exhibit Multiple Transcriptomic Changes(A) Evolution of TMP-resistant 32xR *E. coli*: TMP-sensitive WT *E. coli* were adapted to TMP in a stepwise manner over 2.5 days. The adaptation was initiated by growing WT in sub-inhibitory (0.25xMIC) TMP concentration of 0.125 μg/mL to A~600~ \~ 0.6 (green filled circle) followed by inoculation in 2x TMP (0.25 μg/mL). This was done iteratively by doubling the concentration in each step till *E. coli* adapted to 16 μg/mL TMP. Line at the bottom indicates time after which the culture reached A~600~ \~ 0.6 in a particular concentration.(B) log~2~FC values of 397 DEGs in biological replicates of 4xR and 32xR *E. coli*. The FC of a gene is the mean of the FC of biological replicates of 4xR or 32xR. In general, FC is seen to be higher in 32xR as compared with 4xR.(C) Common DEGs in 4xR and 32xR: 75 and 46 genes were commonly downregulated (D) and upregulated (U), respectively.(D) Gene Ontology (GO) Biological Process enrichment of DEGs in 32xR *E. coli*: Biofilm formation, response to pH, and SOS response were significantly enriched in upregulated DEGs (red), whereas motility and amino acid biosynthesis were enriched in downregulated DEGs (blue).

Transcriptomes of TMP-resistant (4xR1, 4xR2, 32xR1, and 32xR2) and WT *E. coli* were profiled using a DNA microarray. The 4xR *E. coli* were TMP-resistant intermediates in the evolution of 32xR *E. coli* from the WT ([Figure 1](#fig1){ref-type="fig"}A). To prevent loss of resistance, resistant *E. coli* were grown in media containing appropriate concentration of TMP; the biological replicates of WT, 4xR, and 32xR *E. coli* were grown to mid-log phase in M9, M9-2 μg/mL TMP, and M9-16 μg/mL TMP. Expression values were obtained for 4,021 genes and found to be highly correlated (≥0.95) among the two biological replicates of each type of *E. coli*. Therefore, for each gene, we considered the mean of the two expression values for all analyses. Since the transcriptomes of WT *E. coli* growing in sub-inhibitory antibiotic concentrations are diverse, we compared the transcriptomes of the resistant bacteria with that of the WT grown in the absence of the drug ([@bib4]).

Totally, 397 unique differentially expressed genes (DEGs) (\|log~2~fold-change (FC)\| ≥ 1 and Benjamini-Hochberg FDR-corrected p value \< 0.05) were identified in the TMP-resistant (4xR and 32xR) *E. coli*. For the 4xR *E. coli*, 173 DEGs were identified, whereas nearly twice as many, 345, were found in the 32xR *E. coli* ([Table S1](#mmc1){ref-type="supplementary-material"}). FC was observed to be higher in 32xR *E. coli* ([Figure 1](#fig1){ref-type="fig"}B). With the RNA samples used for microarray, the FC values for a few DEGs were re-estimated with qPCR and found to agree with the FC obtained from the microarray ([Table S2](#mmc1){ref-type="supplementary-material"}). Between the 32xR and 4xR strains, 46 and 75 DEGs were seen to be commonly upregulated and downregulated, respectively ([Figure 1](#fig1){ref-type="fig"}C). No DEG upregulated in 4xR *E. coli* was seen to be downregulated in 32xR *E. coli* and vice versa, suggesting an absence of change in survival strategy as *E. coli* adapt to higher concentrations of TMP ([Figure 1](#fig1){ref-type="fig"}C). Adaptation to TMP was observed to occur through perturbation of several biological processes. SOS response, response to acidic pH, viral process, biofilm formation, and lipopolysaccharide metabolism were seen to be enriched in upregulated genes, whereas most of the downregulated genes were seen to be involved in chemotaxis, amino acid metabolism, pyrimidine biosynthesis, and siderophore and molybdate transport ([Figure 1](#fig1){ref-type="fig"}D). Some of these processes have also been observed in WT *E. coli* grown in sub-inhibitory TMP indicating coherence between stress response and resistance to TMP ([@bib24]).

Unbiased Identification of Altered Interactions, Paths, and Cross Talk in TMP-Resistant *E. coli* {#sec2.2}
-------------------------------------------------------------------------------------------------

We were interested in knowing if the DEGs were functionally connected in any way. A knowledge-based functional interactome, i.e., a genome-scale protein-protein interaction network, integrated with phenotype-specific gene expression data is an elegant tool for studying underlying cross talk. Such networks have been instrumental in the identification of isoniazid resistance mechanisms in mycobacteria and biomarkers for tuberculosis ([@bib17], [@bib22]). In keeping with this, a functional interactome, *E. coli* protein-protein interaction network (EcPPIN), was constructed, integrated with transcriptome information, and used to study the cross talk underlying TMP resistance with the goal of identifying targetable components, if any.

EcPPIN was constructed using functional interaction data (regulatory, physical binding, metabolic, etc.) between 3,498 genes and had 24,542 edges obtained from public databases and the literature (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). Furthermore, a condition-specific network, 32xNet, which captures gene expression perturbations associated with TMP resistance, was generated by integrating the differential transcriptome of WT and 32xR *E. coli* into EcPPIN (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}) ([Figure 2](#fig2){ref-type="fig"}A). Approximately 8.4 million shortest paths were detected in 32xNet and ranked based on normalized path costs (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). A subset of top-ranked shortest paths that (1) was significantly enriched in DEGs (hypergeometric p value \< 0.05) and (2) contained ≥75% of all observed DEGs was considered desirable for the identification of high-confidence resistance-associated perturbations. The top-ranked 0.4% shortest paths were observed to satisfy these criteria; enrichment p value = 0.003; 269 DEGs (78%) ([Table S3](#mmc1){ref-type="supplementary-material"}). Since we were interested only in the interactions that are directly linked to or possibly impart TMP resistance, only the edges involving at least one DEG were considered, leading to the selection of 570 genes connected by 1,177 edges. Interestingly, most of the 1,177 edges, albeit a very small portion of the EcPPIN, formed a connected sub-network, 32xTopNet ([Figure 2](#fig2){ref-type="fig"}B). This connectedness indicated cross talk, i.e., individual processes influence each other and are perhaps orchestrated through common control elements.Figure 2Cross Talk between Processes Perturbed by TMP Is Identified from 32xTopNet(A) Flow chart showing steps involved in extraction of 32xTopNet from 32xNet.(B) 32xTopNet: filled diamonds (DEGs) and circles (non-DEG genes) represent nodes and lines connecting them are knowledge-based functional interactions. The nodes are colored based on FC.(C) Cross talk between processes perturbed by TMP viz. GASR, motility, biofilm, and folate metabolism inferred from the 32xTopNet. Genes belonging to each process are shown in a different shape. Like in (B), node colors signify extent of upregulation or downregulation.

Edge-weight-based clustering, which leverages the occurrence of dense connections between groups of genes belonging to the same process, was used to identify processes perturbed by TMP in the 32xTopNet (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). Twenty-six clusters (C1 to C26) of size ≥ 4 (p value \< 0.05) were obtained ([Figure S2](#mmc1){ref-type="supplementary-material"}). Clusters were functionally annotated based on the annotations of its members as per EcoCyc ([@bib10]). Of the 26 clusters, genes in 11 (C2, C3, C6, C8, C10, C14, C16, C18, C21, C22, C26) were seen to be involved in stress-response processes, whereas genes in 5 others (C5, C13, C15, C17, C19) were metabolism related ([Table 1](#tbl1){ref-type="table"}). Amino acid biosynthesis, aerobic respiration, and glycine-cleavage complex in the folate pathway were among the perturbed metabolic processes. SOS-response-DNA repair, glutamate-dependent acid-stress response (GASR), biofilm formation, superoxide detoxification, and e14 prophage were among the active stress response mechanisms. Some of these are of relevance to pathogenesis and host colonization. Using mouse models of human UTI, it has been reported that the induction of SOS response is important for survival of uropathogenic *E. coli* in the bladder epithelial cells of immunocompetent mice ([@bib12]). Similarly, biofilm formation has been linked to persistence and relapse of UTIs ([@bib27]). We confirmed biofilm formation of the resistant *E. coli* using crystal violet staining and scanning electron microscopy. 32xR *E. coli* grown both in the absence and presence of 16 μg/mL TMP were seen to form more biofilm than the WT grown in the absence of TMP ([Figure S3](#mmc1){ref-type="supplementary-material"}).Table 1Clusters Identified in 32xTopNetIDp ValueSizeMember GenesAnnotationC1045*[cheA]{.ul}*, *[cheB]{.ul}*, *[cheW]{.ul}*, *[cheY]{.ul}*, *[cheZ]{.ul}*, *[flgA]{.ul}*, *[flgB]{.ul}*, *[flgC]{.ul}*, *[flgD]{.ul}*, *[flgE]{.ul}*, *[flgF]{.ul}*, *[flgG]{.ul}*, *[flgH]{.ul}*, *[flgI]{.ul}*, *[flgJ]{.ul}*, *[flgK]{.ul}*, *[flgL]{.ul}*, *[flgM]{.ul}*, *[flgN]{.ul}*, *[flhB]{.ul}*, *[fliA]{.ul}*, *[fliC]{.ul}*, *[fliD]{.ul}*, *[fliE]{.ul}*, *[fliF]{.ul}*, *[fliG]{.ul}*, *[fliH]{.ul}*, *[fliI]{.ul}*, *[fliJ]{.ul}*, *[fliK]{.ul}*, *[fliL]{.ul}*, *[fliM]{.ul}*, *[fliN]{.ul}*, *[fliO]{.ul}*, *[fliP]{.ul}*, *[fliQ]{.ul}*, *[fliS]{.ul}*, *[fliT]{.ul}*, *[fliZ]{.ul}*, *[motA]{.ul}*, *[motB]{.ul}*, *[tap]{.ul}*, *[tar]{.ul}*, *[ycgR]{.ul}*, *[yhjH]{.ul}*Flagellar assembly and chemotaxisC20.0027*uvrC*, ***umuC***, *dnaN*, *sbcC*, *uvrD*, ***ruvA***, *uvrB*DNA repairC30.0047***ygiW***, ***ygiV***, ***dinJ***, ***ygiT***, ***yafQ***, ***mqsR***, *hipA*Biofilm regulationC40.0055*sra*, ***rmf***, *cspD*, ***glgS***, *ychH*C50.0058*[aceB]{.ul}*, *[aceK]{.ul}*, *arcA*, ***betB***, ***betI***, ***hybO***, *[maeA]{.ul}*, *[ndh]{.ul}*Aerobic respirationC60.0065*ycgF*, ***ycgZ***, ***ymgA***, ***ymgB***, ***ymgC***Biofilm architectureC70.0077*dcm*, *deoR*, *hsdR*, *hsdS*, ***mcrA***, *[ompT]{.ul}*, *yjaA*DNA modificationC80.00716*csgD*, *[fliZ]{.ul}*, ***gadA***, ***gadB***, ***gadC***, ***gadE***, ***gadX***, *gadW*, *[gltB]{.ul}*, *[gltD]{.ul}*, ***hdeA***, ***hdeB***, ***hdeD***, ***mdtE***, *slp*, ***yhiD***Glutamate-dependent acid stress responseC90.0114*cysB*, *tauA*, *tauB*, *yoaC*Sulfur provisionC100.0116***intE***, ***xisE***, ***ymfJ***, ***ymfM***, ***ymfT***e14 prophage proteinC110.0134***frc***, *hyfA*, *hyfC*, *hyfD*Hydrogenase subunitC120.0134***aspA***, *[fdnH]{.ul}*, *narL*, ***ydhY***Nitrate/nitrite responseC130.0154*[gcvH]{.ul}*, *[gcvP]{.ul}*, *[gcvT]{.ul}*, *purH*Glycine cleavageC140.0154*nth*, *[rsxD]{.ul}*, *[rsxE]{.ul}*, *[rsxG]{.ul}*SoxSR reducing systemC150.01711*argR*, *arnB*, *[carA]{.ul}*, *[carB]{.ul}*, *gdhA*, *[gltB]{.ul}*, *[gltD]{.ul}*, *gpmM*, *hisC*, *[serA]{.ul}*, *serC*Amino acid biosynthesisC160.0187*[fimI]{.ul}*, *ihfB*, ***matA***, *matC*, *yagW*, *yagX*, *ypdA*Fimbrial-associated proteinsC170.0196*[aceA]{.ul}*, *citT*, *gcl*, *ghrA*, *scpC*, *ttdT*Glyoxylate metabolism and succinate transportC180.0196*rpoS, ycgF*, ***ycgZ***, ***ymgA***, ***ymgB***, ***ymgC***Biofilm architectureC190.02313*argR*, ***gadA***, ***gadE***, *gadW*, ***gadX***, *[gltB]{.ul}*, *[gltD]{.ul}*, *hdeD*, *serC*, *slp*, ***ybaS***, ***ybaT***, ***yhiM***Glutamate metabolismC200.02411*[cheA]{.ul}*, *[cheB]{.ul}*, *[cheR]{.ul}*, *[cheW]{.ul}*, *[cheY]{.ul}*, *[cheZ]{.ul}*, *[fliA]{.ul}*, *[motA]{.ul}*, *[tap]{.ul}*, *[tar]{.ul}*, *[tsr]{.ul}*ChemotaxisC210.0304*nth*, *rsxA*, *[rsxD]{.ul}*, *[rsxE]{.ul}*SoxSR reducing systemC220.0304*hipA*, ***mqsR***, ***ygiV***, ***ygiW***Stress responseC230.0306*clpP*, *degP*, ***hflB***, ***obgE***, *rrmJ*, *yhbE*C240.0329*[cheA]{.ul}*, *[cheB]{.ul}*, *[cheR]{.ul}*, *[cheW]{.ul}*, *[cheY]{.ul}*, *[cheZ]{.ul}*, *[tap]{.ul}*, *[tar]{.ul}*, *[tsr]{.ul}*ChemotaxisC250.04016*[cheA]{.ul}*, *[cheB]{.ul}*, *[cheR]{.ul}*, *[cheW]{.ul}*, *[cheY]{.ul}*, *[cheZ]{.ul}*, *[flgK]{.ul}*, *[flgL]{.ul}*, *[fliA]{.ul}*, *[fliS]{.ul}*, *[motA]{.ul}*, *[tap]{.ul}*, *[tar]{.ul}*, *[tsr]{.ul}*, *[ycgR]{.ul}*, *[yhjH]{.ul}*ChemotaxisC260.0436***rcsA***, *wcaA*, ***wcaE***, ***wcaF***, *wzc*, *yjbE*Colanic acid biosynthesis[^2]

Most clusters contained genes belonging to a single process, whereas some represented multiple processes. Motility regulator *fliZ* was captured in both C1 and C8, which contain mainly motility and GASR genes, respectively ([Table 1](#tbl1){ref-type="table"}). FliZ negatively regulates GASR through the repression of GASR activator *gadE*, whereas, another GASR regulator, GadX, activates *rpoS*, which antagonizes *fliA* and *fliZ* expression ([Figure 2](#fig2){ref-type="fig"}C) ([@bib3], [@bib19]). Therefore, in the 32xR *E. coli*, the downregulation of *fliZ* can be linked to de-repression of GASR activator *gadE* and, as a consequence, induction of GASR. FliZ is a negative regulator of *csgD* expression, a transcription factor involved in biofilm formation and vice versa, whereas RpoS positively regulates *csgD* transcription through c-di-GMP ([Figure 2](#fig2){ref-type="fig"}C) ([@bib16], [@bib20], [@bib31]). In keeping with this, diguanylate cyclases (*yeaI*, *ycdT*) were found to be upregulated in 32xR *E. coli* ([Table S1](#mmc1){ref-type="supplementary-material"}). Finally, and remarkably, a previously identified interaction between *csgD* and *glyA* (serine hydroxymethyltransferase) seen in the 32xTopNet highlighted the cross talk between a stress-response mechanism, i.e., biofilm formation and the folate pathway ([Figure 2](#fig2){ref-type="fig"}C) ([@bib2]).

Emergent Vulnerability in TMP-Resistant *E. coli* {#sec2.3}
-------------------------------------------------

GlyA catalyzes the formation of 5,10-methylene tetrahydrofolate (5,10-mTHF) and glycine from serine and THF. The glycine cleavage complex (GcvTPH) (found in C13) also synthesizes 5,10-mTHF from THF; however, it utilizes glycine instead of serine. The 5,10-mTHF produced by these reactions is used for the synthesis of dTMP by ThyA. Both GlyA and GcvTPH lie directly downstream of FolA in the folate pathway ([Figure 2](#fig2){ref-type="fig"}C). A recent study by Minato et al. showed that the deletion of either *gcv* or *glyA* did not improve susceptibility of WT *E. coli* to TMP ([@bib13]). This could be because these two reactions are functionally redundant. Since *gcvTPH* was downregulated in the 32xR *E. coli* ([Table S1](#mmc1){ref-type="supplementary-material"}), the data suggested that the resistant *E. coli* critically depend on *glyA* for production of 5,10-mTHF and subsequently the nucleotides and DNA. Since this dependence on GlyA is unique to the resistant strains, we hypothesized that it is a new vulnerability that has emerged in association with TMP resistance and that *E. coli* devoid of GlyA activity cannot sustain resistance. To confirm this, we first generated *glyA* knockouts of the 32xR1 and 32xR2 *E. coli* ([Figure S4](#mmc1){ref-type="supplementary-material"}). The knockouts were observed to grow satisfactorily ([Figure S4](#mmc1){ref-type="supplementary-material"}). The MIC of TMP for 32xR1:Δ*glyA* and 32xR2:Δ*glyA* was recorded to be 8 and 4 μg/mL, respectively, which translated to a 32-fold decrease in MIC for 32xR2 and more than 100-fold decrease in MIC for 32xR1. Furthermore, to test if our findings hold true for clinical strains of pathogenic *E. coli*, we created a *glyA* knockout of an MDR strain of uropathogenic *E. coli* isolated from a patient with acute UTI. This clinical isolate (CI) was resistant to therapeutic concentrations of ampicillin, piperacillin/tazobactam, cephamycin, cephalosporin antibiotics, cotrimoxazole, ciprofloxacin, and norfloxacin (sensitivity profiling obtained from the hospital repository). It was resistant to TMP with an MIC of 1,024 μg/mL and showed an upregulation GASR, *csgD*, and *glyA* as compared with WT even in the absence of TMP. Like the 32xR1 and 32xR2 *E. coli*, this clinical isolate exhibited slight but significant upregulation of *glyA* and *folA* and downregulation of *gcvT* in the presence of 16 μg/mL and CI:Δ*glyA* showed no growth defect ([Tables S1](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}, [Figure S5](#mmc1){ref-type="supplementary-material"}). However, it did not contain mutations in the chromosomal *folA* indicating that the high resistance could be due to the presence of plasmid-borne naturally resistant dihydrofolate reductase enzymes like in most clinical isolates and not the mutation/overexpression of chromosomal *folA* like in 32xR *E. coli*. Remarkably, the MIC of TMP for CI:Δ*glyA* was also observed to be 8 μg/mL, which, like for 32xR1, translated to a \~100-fold decrease. Collectively, these data showed that the dependence on *glyA* is indeed an emergent vulnerability associated with TMP resistance.

Co-targeting GlyA Retards Acquisition of TMP Resistance {#sec2.4}
-------------------------------------------------------

We observed that the upregulation of *glyA* and biofilm formation occurs even when WT is grown in sub-inhibitory concentrations of TMP ([Figure S6](#mmc1){ref-type="supplementary-material"}). Specifically, WT grown at 0.125 μg/mL (0.25 x MIC) TMP showed \~3-fold higher expression of *glyA* (as compared with WT grown in absence of TMP) with concomitant downregulation of *gcvT* suggesting that GlyA activity is necessary to combat TMP stress ([Table S4](#mmc1){ref-type="supplementary-material"}). Therefore, we asked if GlyA is necessary for adaptation to TMP. Toward this, we carried out a comparative evolution experiment with *E. coli* K12 BW25113 and BW25113:Δ*glyA* as previously described ([@bib33]). The experiment was performed to simulate the adaptation to TMP over the course of a standard UTI treatment. (Note: Depending on the severity of the infection and the Food and Drug Administration\'s \[FDA\] guidelines \[<https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/17943s16lbl.pdf>\], TMP is prescribed for 3--14 days with dosage every 12 \[100 mg\] or 24 h \[200 mg\]. As per the FDA reports, mean peak serum and urine concentrations of 1--2.5 and 30--160 μg/mL, respectively, are achieved 1--4 h after oral administration of a single dose of 100 mg.) Each replicate was exposed to different concentrations of TMP for 12 h post-incubation; *E. coli* growing at the highest concentration were selected for further propagation. Sub-culturing was carried out every 12 h over a period of 14 days. For each 12h period, for each strain, growth observed (A~600~) in a well containing the replicate grown in absence of TMP was considered as the positive control ([Figure 3](#fig3){ref-type="fig"}A). The well from which the bacteria were to be selected for subsequent inoculation had to have A~600~ ≥ A~600~ of the positive control ([Figure 3](#fig3){ref-type="fig"}A). To account for the differences in the growth rate between BW25113 and BW25113:Δ*glyA*, resistance gained at equivalent number of generations was compared.Figure 3Comparative Evolution Shows Slower Adaptation to TMP in Absence of *glyA*(A) Comparative evolution experiment schematic: Dilutions of TMP were prepared in a 96-well plate and inoculated with overnight cultures of BW25113 or BW25113:Δ*glyA*. Culture from well with the highest TMP concentration was used for inoculating plate for the next day provided growth in that well was comparable with growth in the absence of TMP (A~600~ ≥ A~600~ of corresponding well without TMP).(B) Adaptation trajectories to TMP in six biological replicates of BW25113 (blue) and its corresponding BW25113:Δ*glyA* (red) over \~180 generations are shown. Each point for a particular number of generations for a particular replicate represents the maximum TMP concentration at which satisfactory growth (A~600~ ≥ A~600~ of corresponding well without TMP) was observed. Adaptation trajectory of each replicate is shown in a dotted line connecting the points for that replicate across all generations. The mean adaptation trajectory for BW25113 or BW25113:Δ*glyA* is shown in a solid line.(C) Plot shows the mean resistance gained at a particular number of generations for BW25113 or BW25113:Δ*glyA*. For each replicate, the ratio of concentration at which it grows after a particular number of generations and the concentration at which it grew on the first day (after \~12 generations) is calculated. Thus, each ratio represents the fold increase in resistance. Six ratios are obtained per strain and the mean ± SD of these ratios is shown for a particular number of resistant. Since the number of generations completed every 12 h is roughly the same for the two strains, for the purpose of comparison, the BW25113 ratios have also been plotted using the number of generations obtained for BW25113:Δ*glyA*. Between \~100 and 140 generations (\~8--10.5 days), BW25113 (blue) is significantly more resistant to TMP than BW25113:Δ*glyA* (red) (p value \< 0.05; indicated by ∗).

Both strains completed \~180 generations over 14 days, of which \~120 generations were completed over 10 days ([Table S5](#mmc1){ref-type="supplementary-material"}). The average number of generations completed every 12 h was similar too ([Table S5](#mmc1){ref-type="supplementary-material"}). On the fifth day (\~60 generations) the maximum concentration at which BW25113 and BW25113:Δ*glyA* were observed to grow were 8 and 2 μg/mL, respectively ([Figure 3](#fig3){ref-type="fig"}B). This suggested that BW25113:Δ*glyA* could still be inhibited by the physiologically encountered concentration of TMP, whereas BW25113 could not. In the period between \~100 and 140 generations (\~8--10.5 days), BW25113 was significantly more TMP resistant as compared with BW25113:Δ*glyA* ([Figure 3](#fig3){ref-type="fig"}C). After 11.5 days, ≥50% BW25113:Δ*glyA* replicates acquired resistance to ≥4 μg/mL, which is higher than the therapeutic serum concentration. However, this lies significantly outside the typical length of TMP treatment regimens for uncomplicated UTIs, i.e., 3 days ([@bib8]). In summary, the experiment suggested that, in comparison with BW25113, BW25113:Δ*glyA* show delayed acquisition of low levels of TMP resistance.

Concluding Remarks {#sec2.5}
------------------

Although overexpression of a resistant DHFR directly provides TMP resistance in 32xR *E. coli*, the concomitant alterations in expression of a large number of genes (\~8% of the genome) indicates that TMP resistance is a multifaceted response. Integration of the differential transcriptome of WT and 32xR *E. coli* into EcPPIN and an unbiased mining of the condition-specific network 32xNet not only revealed the cross talk between genes involved in different stress response and metabolic pathways perturbed by TMP but also led to the identification of an emergent vulnerability-critical dependence on GlyA. This vulnerability emerges from the multipronged role of GlyA, which ensures uninterrupted DNA synthesis via 5,10-mTHF and dTMP production, protein synthesis, and curli production through glycine production. We show that, even in the presence of primary resistance mechanisms such as the overexpression of a mutant chromosomal DHFR and associated beneficial perturbations viz. activation of the SOS/DNA-repair response and biofilm formation and, possibly, plasmid-borne naturally resistant dihydrofolate reductases in the clinical isolate, deletion of *glyA* rescues sensitivity to TMP to a large extent. The success of *glyA* as a target is attributable to its position in the folate pathway, i.e., downstream of THF biosynthesis where most dihydrofolate reductase activity-based resistance mechanisms functionally converge. Previous studies show that SHMT (GlyA) knockdown induces apoptosis in lung cancer cells and challenges viability in *P. falciparum* ([@bib18], [@bib21]). Since we also show that targeting this resistance-associated emergent vulnerability decelerates the acquisition of resistance in wild-type TMP-sensitive *E. coli*, a GlyA inhibitor used in combination with TMP presents a promising strategy for treating UPEC UTIs.

Limitations of the Study {#sec2.6}
------------------------

1.Although *E. coli* lacking *glyA* show slower adaptation to TMP, it is possible that more than one TMP-adaptation strategy exist and that the outcomes of evolution *in vivo* and *in vitro* (in a controlled laboratory environment) are different.2.Resistance mechanisms in laboratory-evolved and clinical *E. coli* may differ. It is difficult to predict the outcome of targeting *glyA* in clinical strains that are resistant to TMP through non-folate pathway-dependent mechanisms, e.g., efflux pumps and drug avoidance via biofilm formation.3.Prediction of the cross talk between processes depends on the topology of the network and is, therefore, limited by the knowledge of functional interactions in *E. coli.*

Methods {#sec3}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec1}
==========================

The accession ID of the microarray expression data reported in this paper is ArrayExpress: [E-MTAB-6536](array-express:E-MTAB-6536){#intref0015}. R code for analysis of expression data, EcPPIN, and toy networks and scripts for weighted network generation and shortest path computation are made available in a supplementary zipped folder.
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[^1]: Lead Contact

[^2]: Clusters of size 4 or more were identified in 32xTopNet. The first column provides the cluster ID in which the number specifies the rank. Clusters have been annotated based on the genes they contain. Annotation was possible only for clusters with majority of genes sharing a common ontology based on primary literature reports. Downregulated genes are underlined, and upregulated genes are shown in bold (log~2~FC values in [Table S1](#mmc1){ref-type="supplementary-material"}).
